The main APIs are authorized the foreign markets access through CEP, EDMF or DMF registration and cGMP inspection, and more than 70% of APIs are exported to Europe, America and South East Asia etc. The market share of Ribostamycin Sulfate, Netilmicin Sulfate and Spiramycin ranks the top three in the international market, and that of Fleroxacin, Rifapentine and Sisomicin Sulfate etc ranks at the forefront of the domestic market.